Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03546972
Other study ID # 2017-0507
Secondary ID NCI-2018-0127520
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 17, 2017
Est. completion date November 30, 2024

Study information

Verified date March 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot trial studies how well a diabetes prevention program with or without hunger training works in helping to lower breast cancer risk in obese participants. A diabetes prevention program involves learning about and receiving materials on different strategies to encourage weight loss, and hunger training involves learning how to recognize hunger. It is not yet known whether adding hunger training to a diabetes prevention program helps participants control their weight that could reduce the risk of some cancers.


Description:

PRIMARY OBJECTIVES: I. Determine the feasibility of adding hunger training to the Diabetes Prevention Program (DPP) using the following criteria: accrual rates > 50%, attrition rates < 20% and, in the DPP-plus-hunger training (HT) group, training protocol adherence rates > 75%. SECONDARY OBJECTIVES: I. Estimate the magnitude of effect sizes and variation in outcome variables for the DPP-only and DPP-plus-HT interventions on changes in weight; in metabolic and breast cancer risk biomarkers (e.g., fasting insulin and blood glucose [BG] levels, levels of glycosylated hemoglobin, insulin resistance, adiponectin, interleukin-6, and C-reactive protein); and in proposed behavioral mediators (e.g., reduction in total energy intake, overall eating frequency, percent of eating events occurring at or below the average fasting blood BG level). II. Examine the mediation effects of proposed mechanisms of the interventions related to individual-level behavioral measures of eating self-regulation on the proposed outcomes using a multimodal approach of validated questionnaires and reliable ecological momentary assessment method. OUTLINE: Participants are randomized to 1 of 2 groups. GROUP A: Participants take part in DPP once a week over 1 hour for 16 weeks. GROUP B: Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 51
Est. completion date November 30, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - Body Mass Index (BMI) >= 27 kg/m^2. - At high risk of developing breast cancer defined by one or more of the following: Gail model lifetime risk > 20% or a 5 year risk >1.66%, a history of deleterious BRCA1/2 mutation or mantle radiation, a history of ductal cancer in situ, or a history of high risk premalignant breast lesion. - 12 months without a period/menstrual cycle or having had a bilateral oophorectomy. - Ability to take digital time stamped photos. - Internet access (daily). - Reports being proficient in English (can read/write and speak fluently). Exclusion Criteria: - Previous participation in this trial. Participation is defined as screening. Re-screening is not allowed except for individuals excluded for BMI. Patients previous screened as ineligible due to BMI are allowed to be re-screened and enrolled if eligible. - Has a current measured BMI less than 27 kg/m^2. - Reports being unwilling to use Continuous Glucose Monitor (CGM), which requires daily blood sampling by finger pricks. - Currently being actively treated for cancer other than nonmelanoma skin cancer. - Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests. - Reported current diagnosis or history of type I diabetes or type 2 diabetes. - Reported use of oral antidiabetic agents (OADs). - Current use of any drug (except metformin) or anticipated change in concomitant medication, which the investigator's opinion could interfere with the glucose metabolism (e.g. systemic corticosteroids). - Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator). - Previous or current treatment with GLP-1 receptor agonists (e.g. exenatide, liraglutide). - Fasting blood glucose level > 126 and glycosylated hemoglobin (HbA1c) > 7%. - Subjects considered by the investigator as unsuitable for the study for reasons not otherwise stated.

Study Design


Intervention

Other:
Behavioral, Psychological or Informational Intervention
Take part in DDP
Behavioral, Psychological or Informational Intervention
Take part in HT
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by recruitment rate Measured by percentage of participants who enroll in the study. Up to 2 years
Primary Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by drop-out rates Measured by percentage of participants who leave the study. Up to 2 years
Primary Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by completion rates Measured by percentage of participants who complete the study. Up to 2 years
Secondary Changes in weight loss Will use linear regression to study the effects of participant characteristics (i.e., weight history) and their interactions with the treatment groups. Baseline to 2 years
Secondary Changes in metabolic and breast cancer risk biomarkers Biomarkers will be assessed through blood draws. Baseline to 2 years
Secondary Changes in proposed behavioral mediators through survey Eating patterns will be assessed through survey ASA24 (Automated Self-assessment). At baseline and at 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2